As the tumor grows, cancer cells and signal molecules in the TME recruit regulatory CD4+ T-cells (Tregs), responsible to inhibit T-cell responses, specifically priming, activation and cytotoxicity of effector immune cells (Figure 1) [69]. The gene discussed is CD4; the disease is neoplasm.